Rabies Treatment

Rabies Treatment

Global Rabies Treatment Market to Reach US$6.1 Billion by 2030

The global market for Rabies Treatment estimated at US$4.6 Billion in the year 2023, is expected to reach US$6.1 Billion by 2030, growing at a CAGR of 4.2% over the analysis period 2023-2030. Vaccines, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth in the Rabies Immune Globulin (RIG) segment is estimated at 3.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 7.1% CAGR

The Rabies Treatment market in the U.S. is estimated at US$1.2 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR.

Global Rabies Treatment Market - Key Trends and Drivers Summarized

Rabies Treatment: Critical Interventions for a Life-Threatening Disease

Rabies is a viral disease that affects the central nervous system, leading to severe neurological symptoms and, if left untreated, death. The virus is typically transmitted through the bite of an infected animal, with dogs being the most common source of human rabies infections globally. Once symptoms appear, rabies is almost always fatal, making prompt and effective treatment critical for survival. The standard treatment for rabies exposure involves post-exposure prophylaxis (PEP), which includes thorough wound cleansing, administration of rabies immunoglobulin (RIG), and a series of rabies vaccinations. Early intervention with PEP is crucial, as it can prevent the virus from progressing to the central nervous system, thereby averting the onset of symptoms. Rabies treatment is a vital public health measure, particularly in regions where rabies is endemic and access to healthcare is limited.

How Are Technological Advancements Improving Rabies Treatment?

Technological advancements have significantly improved the effectiveness, accessibility, and affordability of rabies treatment, contributing to better outcomes for individuals exposed to the virus. Advances in vaccine technology have led to the development of more potent and stable rabies vaccines that provide long-lasting immunity with fewer doses. The introduction of monoclonal antibodies as an alternative to traditional rabies immunoglobulin has enhanced the availability and consistency of PEP, particularly in regions where supply shortages of human or equine RIG are common. Additionally, innovations in diagnostic tools have improved the accuracy and speed of rabies detection, enabling healthcare providers to administer timely and appropriate treatment. Mobile health (mHealth) applications and telemedicine platforms are also playing a role in expanding access to rabies treatment by providing remote consultation and guidance to healthcare workers in rural and underserved areas. These technological advancements are not only improving the standard of care for rabies patients but are also supporting global efforts to eliminate the disease.

What Are the Key Components and Benefits of Rabies Treatment Protocols?

Rabies treatment protocols involve several key components that work together to prevent the onset of the disease and ensure the best possible outcome for exposed individuals. The first step in rabies treatment is thorough wound cleaning with soap and water, which helps remove the virus from the wound site and reduce the risk of infection. This is followed by the administration of rabies immunoglobulin (RIG) to provide immediate passive immunity, especially in cases where the exposure is deemed high-risk. The final component is the administration of a series of rabies vaccinations, which stimulate the body`s immune response to produce antibodies that neutralize the virus. The benefits of following these treatment protocols include preventing the progression of rabies to its fatal stage, providing long-term immunity to the virus, and reducing the need for emergency interventions in the future. The effectiveness of rabies treatment is highly dependent on the timely administration of PEP, making awareness and access to treatment crucial in preventing deaths from rabies.

What Factors Are Driving the Growth in the Rabies Treatment Market?

The growth in the Rabies Treatment market is driven by several factors. The increasing prevalence of rabies in certain regions, particularly in Africa and Asia, is a significant driver, as these areas require robust treatment strategies to manage the disease burden. Technological advancements in vaccine development and the introduction of monoclonal antibodies are also propelling market growth by improving the efficacy and availability of rabies treatment options. The rising awareness of rabies prevention and the importance of early treatment are further boosting demand for rabies vaccines and immunoglobulin, as more individuals seek PEP following potential exposure. Additionally, global public health initiatives aimed at rabies elimination, such as mass dog vaccination campaigns and community education programs, are contributing to market growth by increasing the need for rabies vaccines and related treatments. The expansion of healthcare infrastructure in developing countries and the growing use of telemedicine for remote diagnosis and treatment are also supporting the adoption of rabies treatment protocols. These factors, combined with continuous innovation in rabies treatment and prevention, are driving the sustained growth of the Rabies Treatment market.

Select Competitors (Total 12 Featured) -
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Sanofi SA
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Rabies Treatment – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Rabies in Developing Regions Propels Market Growth
Increasing Awareness and Prevention Programs Expands Addressable Market Opportunity
Technological Advancements in Rabies Diagnostics and Vaccines Strengthen Market Position
Growing Focus on Post-Exposure Prophylaxis (PEP) Drives Adoption of Rabies Treatment
Surge in Demand for Human Rabies Immunoglobulin (HRIG) Generates New Opportunities
Development of Monoclonal Antibodies for Rabies Sustains Market Growth
Expanding Applications in Veterinary Medicine Throws Spotlight on Market Potential
Growth in Public Health Initiatives and Vaccination Campaigns Spurs Demand for Rabies Treatment
Rising Adoption of Cost-Effective and Accessible Treatment Solutions Propels Market Expansion
Surge in Demand for Rabies Immunization in High-Risk Populations Expands Market Horizons
Growing Awareness of Rabies Prevention in Pet Ownership and Animal Control Drives Market Adoption
Innovations in Vaccine Delivery Methods Generate New Market Opportunities
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Post-Exposure Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Post-Exposure Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Post-Exposure Prophylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 4: World Rabies Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 5: World Recent Past, Current & Future Analysis for Rabies Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Rabies Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Rabies Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Rabies Immune Globulin (RIG) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Rabies Immune Globulin (RIG) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Rabies Immune Globulin (RIG) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Pre-Exposure Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Pre-Exposure Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Pre-Exposure Vaccination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Rabies Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 17: USA Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 18: USA Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: USA 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 20: USA Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: USA Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: USA 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: Canada 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 26: Canada Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: Canada Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Canada 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
JAPAN
Rabies Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 29: Japan Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: Japan Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Japan 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 32: Japan Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Japan Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Japan 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
CHINA
Rabies Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 35: China Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: China Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: China 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 38: China Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: China Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: China 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
EUROPE
Rabies Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 41: Europe Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Europe Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Europe 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 44: Europe Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Europe Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Europe 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
TABLE 47: Europe Recent Past, Current & Future Analysis for Rabies Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Rabies Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Europe 16-Year Perspective for Rabies Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
FRANCE
Rabies Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 50: France Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: France Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: France 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 53: France Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: France Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: France 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
GERMANY
Rabies Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 56: Germany Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Germany Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Germany 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 59: Germany Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Germany Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Germany 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
ITALY
TABLE 62: Italy Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Italy Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Italy 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 65: Italy Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Italy Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Italy 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
UNITED KINGDOM
Rabies Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 68: UK Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: UK Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: UK 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 71: UK Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: UK Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: UK 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
SPAIN
TABLE 74: Spain Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Spain Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Spain 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 77: Spain Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Spain Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Spain 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
RUSSIA
TABLE 80: Russia Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Russia Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Russia 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 83: Russia Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Russia Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Russia 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Rest of Europe Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Rest of Europe 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Rest of Europe Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Rest of Europe 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Rabies Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Asia-Pacific Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Asia-Pacific 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Asia-Pacific Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Asia-Pacific 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Rabies Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 99: Asia-Pacific Historic Review for Rabies Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Asia-Pacific 16-Year Perspective for Rabies Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
AUSTRALIA
Rabies Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 101: Australia Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Australia Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Australia 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 104: Australia Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Australia Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Australia 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
INDIA
Rabies Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 107: India Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: India Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: India 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 110: India Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: India Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: India 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 113: South Korea Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: South Korea Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: South Korea 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 116: South Korea Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: South Korea Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: South Korea 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: Rest of Asia-Pacific Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: Rest of Asia-Pacific Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
LATIN AMERICA
Rabies Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 125: Latin America Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: Latin America Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: Latin America 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 128: Latin America Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Latin America Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Latin America 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
TABLE 131: Latin America Recent Past, Current & Future Analysis for Rabies Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 132: Latin America Historic Review for Rabies Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Latin America 16-Year Perspective for Rabies Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
ARGENTINA
TABLE 134: Argentina Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Argentina Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Argentina 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 137: Argentina Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Argentina Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Argentina 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
BRAZIL
TABLE 140: Brazil Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Brazil Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Brazil 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 143: Brazil Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Brazil Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Brazil 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
MEXICO
TABLE 146: Mexico Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Mexico Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Mexico 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 149: Mexico Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Mexico Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Mexico 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Rest of Latin America Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Rest of Latin America 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Rest of Latin America Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Rest of Latin America 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
MIDDLE EAST
Rabies Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 158: Middle East Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Middle East Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Middle East 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 161: Middle East Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Middle East Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Middle East 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
TABLE 164: Middle East Recent Past, Current & Future Analysis for Rabies Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 165: Middle East Historic Review for Rabies Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Middle East 16-Year Perspective for Rabies Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
IRAN
TABLE 167: Iran Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Iran Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Iran 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 170: Iran Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: Iran Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Iran 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
ISRAEL
TABLE 173: Israel Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Israel Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Israel 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 176: Israel Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Israel Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Israel 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Saudi Arabia Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Saudi Arabia 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Saudi Arabia Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Saudi Arabia 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 185: UAE Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: UAE Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: UAE 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 188: UAE Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: UAE Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: UAE 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Rest of Middle East Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Rest of Middle East 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Rest of Middle East Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Rest of Middle East 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
AFRICA
Rabies Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 197: Africa Recent Past, Current & Future Analysis for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: Africa Historic Review for Rabies Treatment by Application - Pre-Exposure Vaccination and Post-Exposure Prophylaxis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: Africa 16-Year Perspective for Rabies Treatment by Application - Percentage Breakdown of Value Sales for Pre-Exposure Vaccination and Post-Exposure Prophylaxis for the Years 2014, 2024 & 2030
TABLE 200: Africa Recent Past, Current & Future Analysis for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Africa Historic Review for Rabies Treatment by Product Type - Vaccines and Rabies Immune Globulin (RIG) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Africa 16-Year Perspective for Rabies Treatment by Product Type - Percentage Breakdown of Value Sales for Vaccines and Rabies Immune Globulin (RIG) for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings